

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Anticipated Classification

of this Application:

Class: 435 Subclass: 252.31

Prior Application:

Examiner:

Diana Johannsen

Art Unit:

1634

Asst. Commissioner for Patents Washington, D.C. 20231

SIR:

408.014-CON

This is a request for filing a

Continuation [X]

application under 37 CFR 1.53

Divisional 1

of pending prior Application Serial No. 09/242,588

Juana Magdalena et al Of: Filed on: May 20, 1999

For: FRAGMENTS OF NUCLEIC ACIDS SPECIFIC TO MYCOBACTERIA WHICH ARE MEMBERS OF THE M. TUBERCULOSIS COMPLEX AND THEIR APPLICATIONS FOR THE DETECTION AND THE DIFFERENTIAL DIAGNOSIS OF MEMBERS OF THE M.

TUBERCULOSIS COMPLEX

- Enclosed is a copy of the prior application, 1. [X] including the oath or declaration as originally filed and an affidavit or declaration verifying it (See 8 and 8a for drawing as a true copy. requirements).
- Prepare a copy of the prior application. 2. []
- The Filing fee is calculated below: 3. [X]

CLAIMS AS FILED IN THE PRIOR APPLICATION, LESS ANY CLAIMS CANCELLED BY AMENDMENT BELOW

<u>For</u>	Number <u>Filed</u>	Number <u>Filed</u> Excess of 20	<u>Rate</u>	Basic Fee <u>\$740.00</u>
Total Claims	28	8	X \$18.00 =	\$144.00
Independent Claims	5	Excess of 3	X \$84.00 =	\$168.00
Multiple depend	lent claims	[] Yes \$280.0	00 [] No	\$1052.00

- 4. [X] The Asst. Commissioner is hereby authorized to charge any fees which may be required, or to credit any over-payment to Account No. 02-2275. A duplicate copy of this sheet is enclosed.
 - I hereby certify that this correspondence is being deposited with the U.S. Postal Service as express mail No. <u>EV 068843455 US</u> in an envelope addressed to the Asst. Commissioner for Patents, Washington, D.C. 20231 on <u>February 28, 2002</u>

Date: February 28, 2002

Charles A. Muserlian # 19,683

5. [X] PTO From 2038 for \$\frac{1052.00}{} is enclosed.

6. [X] Cancel in this application original claims

2 to 27 of the prior application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes).

7. [] Amend the specification by inserting before the first line in the sentence;
This is a [] Continuation, [] Division of Serial

No.

- 8. [] Transfer the drawings from the prior application as of the filing date accorded this application. A duplicate copy of this sheet is enclosed for filing in the prior application file. (May only be used before payment of base issue fee).
- 8a. [X] New formal drawings are enclosed.
- 8b. [X] Priority of application Serial No. 96/10277

 Filed: August 19, 1996 in France
 is claimed under 35 USC 119.
- 8c. [X] The certified copy has been filed in the prior application Serial No. 242,588 Filed May 20, 1999
- 9. [X] The prior application is assigned of record to

 1) Institut Pasteur De Lille 2) Institut National

 De La Sante Et De La Recherche Medicale (INSERM)
- The power of attorney in the prior application is to any one of the following: Jordan B. Bierman, Reg. No. 18,629; Charles A. Muserlian, Reg. No. 19,683; Donald C. Lucas, Reg. No. 31,275; all of 600 Third Avenue, New York, N.Y. 10016; Registration No. 18,818; its attorney to file this Declaration with full power of substitution and revocation and to transact all business in the Patent Office connected therewith.

- a. [X] The power appears in the original papers of the prior application.
- b. [] Since the power does not appear in the original papers, a copy of the power in the prior application is enclosed.
- c. [X] Recognize as associate attorney and address all future communications to:

Charles A. Muserlian, Reg. No. 19,683 c/o Bierman, Muserlian and Lucas 600 Third Avenue New York, N.Y. 10016

- 11. [X] A preliminary amendment is enclosed. (Claims added by this amendment have been properly numbered consecutively beginning with the number next following the highest numbered original claim in the prior application).
- 12. [X] I hereby verify that the attached papers are a true copy of prior application Serial No. 09/242,588 as originally filed on March 20, 1999 ...

The undersigned declares further that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the above-identified application or any patent issuing thereon.

Date: February 28, 2002

Charles A. Múserlian

Reg. No. 19,683

Bierman, Muserlian and Lucas 600 Third Avenue New York, N.Y. 10016

"EXPRESS MAIL"	Mailing Label Number	EV 068843455 US
Date of Deposit	: February 28, 2002	

I hereby certify that this correspondence is being deposited with the United States Postal Service "EXPRESS MAIL POST OFFICE TO ADDRESSEE" Service under 37 CFR 1.10 on the date indicated above and is addressed to Asst. Commissioner for Patents, Washington, D.C. 20231.

Charles A. Muserlian

IIIGGETE CEECE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s)

Magdalena, J. et al.

Serial No.

Group Unit: 1634

Filed

Concurrently Herewith

Examiner: Johannsen, D.

For

M. TUBERCULOSIS COMPLEX MEMBERS MYCOBACTERIA SPECIFIC NUCLEIC ACID FRAGMENTS AND THEIR APPLICATIONS FOR THE DETECTION AND DIFFERENTIAL

DIAGNOSIS OF M. TUBERCULOSIS COMPLEX MEMBERS

RESPONSE TO COMMUNICATION FROM EXAMINER

Assistant Commissioner of Patents Washington, D.C. 20231

Dear Sir:

In response to a Communication from the Examiner dated July 31, 2000, applicants provide

the following amendment and remarks.

IN THE SPECIFICATION

Please amend the specification as follows:

On page 4, line 33, after "3'." insert --(SEQ ID NO:3)--.

On page 9, line 31, after "TGC3" insert --(SEQ ID NO:4)--.

On page 9, line 31, after "AGC3'" insert --(SEQ ID NO:5)--.

On page 13, line 18, after "TGC3" insert --(SEQ ID NO:4)--.

On page 13, line 18, after "AGC3" insert --(SEQ ID NO:5)--.

On page 15, line 36, after "CGC-3" insert -- (SEQ ID NO:6)--.

On page 16, line 1, after "ACC-3" insert -- (SEQ ID NO:7)--.

On page 18, line 26, after "GTC-3'" insert --(SEQ ID NO:8)--.

On page 18, line 27, after "3" insert -- (SEQ ID NO:9)--.

On page 20, line 5, after "TCA 3" insert -- (SEQ ID NO:10)--.

On page 20, line 6, after "3" insert -- (SEQ ID NO:11)--.

On page 21, line 31, after "TGC3" insert --(SEQ ID NO:4)--.

On page 21, line 34, after "AGC-3'" insert --(SEQ ID NO:5)--.

IN THE CLAIMS

Please amend the claims as follows:

On page 37, line 35, after "TGC3'" insert --(SEQ ID NO:4)--.
On page 37, line 35, after "AGC3'" insert --(SEQ ID NO:5)--.

REMARKS

Applicants submit herewith a paper copy of a substitute sequence list in response to the Examiner's Communication. Please replace the original sequence list with the substitute sequence list provided herewith. Also enclosed herewith is a computer diskette containing the sequence list. A statement pursuant to 37 CFR §1.825(b) is enclosed, stating that the computer diskette contains an identical sequence list as the paper copy.

No fee is believed due.

Respectfully submitted,

BIERMAN, MUSERLIAN AND LUCAS, L.L.P.

Date: February 28, 2002

By:

Charles A. Muserlian

Reg. No. 19,683

BIERMAN, MUSERLIAN AND LUCAS, L.L.P. 600 Third Avenue New York, NY 10016 (212) 661-8000 (212) 661-8002 Telecopier